Your session is about to expire
← Back to Search
IVX-A12 for Healthy Older Adults
Study Summary
This trial tests a single-dose RSV/hMPV vaccine in healthy older adults, to see if it is safe and effective.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You have previously received an experimental vaccine for respiratory syncytial virus (RSV) or human metapneumovirus (hMPV).You have a serious heart or lung condition that makes you more likely to have severe respiratory syncytial virus (RSV) or human metapneumovirus (hMPV) disease.You are currently sick, with or without a fever, when you are supposed to get the vaccine.Older adults who have health problems that affect their physical, mental, or cognitive abilities, as determined by the study site.You have had severe reactions to vaccines in the past, like anaphylaxis or Guillain-Barré syndrome. You are also allergic to any ingredient in the IVX-121 and/or IVX-241 vaccine, or you have a latex allergy.
- Group 1: IVX-A12 Vaccine - High Dosage Level
- Group 2: IVX-A12 Vaccine - Low Dosage Level
- Group 3: IVX-A12 Vaccine + MF59® - Low Dosage Level
- Group 4: IVX-A12 Vaccine - Medium Dosage Level
- Group 5: IVX-A12 Vaccine + MF59® - Medium Dosage Level
- Group 6: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Might I be eligible to partake in this clinical trial?
"In order to be admitted into the study, candidates must have a healthy subject (HS) score and fall between 60-75 years of age. The trial has capacity for 120 participants."
Are geriatric patients being considered for this investigation?
"For this particular clinical trial, only those aged between 60 and 75 years old are eligible to participate. Those under 18 have access to 51 trials while individuals older than 65 may consider one of the 371 studies available for them."
Are there any remaining spots available for enrollment in this experiment?
"Affirmative. Clinicaltrials.gov has declared that this clinical trial is actively enrolling, having been first posted on September 21st 2022 and recently updated on December 22nd 2022. 120 individuals are being recruited across three sites."
What hazards have been associated with a low dose of the IVX-A12 Vaccine?
"Based on the available data, our team has assigned IVX-A12 Vaccine - Low Dosage Level a safety rating of 1. This first phase trial does not have sufficient evidence to support its efficacy or safety yet."
What is the total enrollment of participants in this clinical experiment?
"Icosavax, Inc. is responsible for the recruitment of 120 suitable candidates across multiple study sites such as CenExcel ACMR in Atlanta and Meridien Clinical Research in Omaha, Nebraska."
Share this study with friends
Copy Link
Messenger